- New Purchases: BCYC, APLS, AYLA, ZNTL, WVE, MCRB, RCOR, ISEE, IGMS, CMMB, CMMB, CDAK, MXCT, CERE, RPHM, TENX, KNSA, KLDO, SRPT, AADI, ALNY, AMYT,
- Added Positions: INBX, IMTX, CMPS, GOSS, BCAB, CRVS, CABA, CLNN, CLNN, LIFE, ACET, ACAD, FOLD, SRRA, VLON, ASMB, YMTX, ASLN, DCTH,
- Reduced Positions: BIIB, CRSP, RLMD, GLPG, MGNX, CMRX, AUTL, XENE, STTK, PCVX, CLDX, VINC, HZNP, INMB, OCUL, LYRA, HEPA, MIST, SCPH, XFOR, IMVT, PASG, VTGN, TARA, ACRS, BLU, EYPT, ITCI, VSTM, PLRX, AVTX, SLDB, TCDA, ODT, ATNX, IPA, SNPX, CBIO, DMAC, NVAX, INCY, TPST, SYBX, QSI, NXTC, STSA, CASI, COGT, SVRA, FNCH, IFRX, SEEL, OVID, IOVA, AGTC, CLVS, DBVT, MBIO, VKTX, FLACU, GNCA, LRMR, ONTX, IVA, HSAQ, ICPT, BLSA, OCUP, VBLT, RGLS, PBYI, GMTX, ANEB, BCLI, BDTX, BXRX, CYTO, PBLA, OTIC, ELDN, CRTX, CYCN, MITO, HARP, ORTX, CRBP, MREO, ATXS, APTO, ALRN,
- Sold Out: ALEC, ANVS, CGEM, CCXI, CHAQ.U, IMAB, RDNT, KDMN, CMLF, ASND, ARPO, ALPN, CYTK, ICAD, ZGNX, BCEL, FULC, ACIU, LLY, PSTX, FREQ, AFMD, ANAB, CCCC, SAVA, CHMA, CARA, FATE, CHAQ,
For the details of Ikarian Capital, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/ikarian+capital%2C+llc/current-portfolio/portfolio
These are the top 5 holdings of Ikarian Capital, LLC- S&P 500 ETF TRUST ETF (SPY) - 300,000 shares, 9.07% of the total portfolio.
- SPDR Biotech ETF (XBI) - 650,000 shares, 5.75% of the total portfolio.
- Biogen Inc (BIIB) - 167,500 shares, 3.34% of the total portfolio.
- Reata Pharmaceuticals Inc (RETA) - 471,400 shares, 3.34% of the total portfolio.
- Horizon Therapeutics PLC (HZNP) - 421,900 shares, 3.25% of the total portfolio.
Ikarian Capital, LLC initiated holding in Bicycle Therapeutics PLC. The purchase prices were between $27.95 and $44.24, with an estimated average price of $35.01. The stock is now traded at around $60.700000. The impact to a portfolio due to this purchase was 1.54%. The holding were 526,500 shares as of 2021-09-30.
New Purchase: Apellis Pharmaceuticals Inc (APLS)Ikarian Capital, LLC initiated holding in Apellis Pharmaceuticals Inc. The purchase prices were between $31.4 and $69.84, with an estimated average price of $56.51. The stock is now traded at around $42.200000. The impact to a portfolio due to this purchase was 0.81%. The holding were 347,545 shares as of 2021-09-30.
New Purchase: Zentalis Pharmaceuticals Inc (ZNTL)Ikarian Capital, LLC initiated holding in Zentalis Pharmaceuticals Inc. The purchase prices were between $46.83 and $73.5, with an estimated average price of $57.7. The stock is now traded at around $74.970000. The impact to a portfolio due to this purchase was 0.43%. The holding were 92,344 shares as of 2021-09-30.
New Purchase: Ayala Pharmaceuticals Inc (AYLA)Ikarian Capital, LLC initiated holding in Ayala Pharmaceuticals Inc. The purchase prices were between $8.13 and $14.09, with an estimated average price of $11.98. The stock is now traded at around $11.540000. The impact to a portfolio due to this purchase was 0.43%. The holding were 538,939 shares as of 2021-09-30.
New Purchase: WAVE Life Sciences Ltd (WVE)Ikarian Capital, LLC initiated holding in WAVE Life Sciences Ltd. The purchase prices were between $4.89 and $7.12, with an estimated average price of $6.07. The stock is now traded at around $4.590000. The impact to a portfolio due to this purchase was 0.34%. The holding were 993,481 shares as of 2021-09-30.
New Purchase: Seres Therapeutics Inc (MCRB)Ikarian Capital, LLC initiated holding in Seres Therapeutics Inc. The purchase prices were between $5.46 and $22.6, with an estimated average price of $9.91. The stock is now traded at around $7.890000. The impact to a portfolio due to this purchase was 0.3%. The holding were 606,554 shares as of 2021-09-30.
Added: Inhibrx Inc (INBX)Ikarian Capital, LLC added to a holding in Inhibrx Inc by 3489.03%. The purchase prices were between $25.18 and $37.81, with an estimated average price of $30.45. The stock is now traded at around $43.715000. The impact to a portfolio due to this purchase was 0.66%. The holding were 289,850 shares as of 2021-09-30.
Added: Immatics NV (IMTX)Ikarian Capital, LLC added to a holding in Immatics NV by 292.22%. The purchase prices were between $11.58 and $15.46, with an estimated average price of $12.71. The stock is now traded at around $11.780000. The impact to a portfolio due to this purchase was 0.6%. The holding were 883,046 shares as of 2021-09-30.
Added: Compass Pathways PLC (CMPS)Ikarian Capital, LLC added to a holding in Compass Pathways PLC by 169.45%. The purchase prices were between $29.03 and $38.62, with an estimated average price of $33.61. The stock is now traded at around $34.737500. The impact to a portfolio due to this purchase was 0.3%. The holding were 229,202 shares as of 2021-09-30.
Added: Gossamer Bio Inc (GOSS)Ikarian Capital, LLC added to a holding in Gossamer Bio Inc by 28.95%. The purchase prices were between $7.25 and $13.23, with an estimated average price of $9.2. The stock is now traded at around $11.820000. The impact to a portfolio due to this purchase was 0.27%. The holding were 1,351,933 shares as of 2021-09-30.
Added: BioAtla Inc (BCAB)Ikarian Capital, LLC added to a holding in BioAtla Inc by 179.93%. The purchase prices were between $29.44 and $43.74, with an estimated average price of $39.07. The stock is now traded at around $27.100000. The impact to a portfolio due to this purchase was 0.26%. The holding were 196,400 shares as of 2021-09-30.
Added: Corvus Pharmaceuticals Inc (CRVS)Ikarian Capital, LLC added to a holding in Corvus Pharmaceuticals Inc by 657.55%. The purchase prices were between $1.89 and $8.53, with an estimated average price of $2.95. The stock is now traded at around $3.865000. The impact to a portfolio due to this purchase was 0.23%. The holding were 757,545 shares as of 2021-09-30.
Sold Out: Alector Inc (ALEC)Ikarian Capital, LLC sold out a holding in Alector Inc. The sale prices were between $21.65 and $39.49, with an estimated average price of $28.1.
Sold Out: Annovis Bio Inc (ANVS)Ikarian Capital, LLC sold out a holding in Annovis Bio Inc. The sale prices were between $30.95 and $120.97, with an estimated average price of $57.77.
Sold Out: Cullinan Oncology Inc (CGEM)Ikarian Capital, LLC sold out a holding in Cullinan Oncology Inc. The sale prices were between $22.56 and $29.68, with an estimated average price of $26.76.
Sold Out: ChemoCentryx Inc (CCXI)Ikarian Capital, LLC sold out a holding in ChemoCentryx Inc. The sale prices were between $13.18 and $19.83, with an estimated average price of $15.55.
Sold Out: Chardan Healthcare Acquisition 2 Corp (CHAQ.U)Ikarian Capital, LLC sold out a holding in Chardan Healthcare Acquisition 2 Corp. The sale prices were between $9.46 and $11.11, with an estimated average price of $10.65.
Sold Out: I-MAB (IMAB)Ikarian Capital, LLC sold out a holding in I-MAB. The sale prices were between $57.18 and $84.43, with an estimated average price of $72.45.
Here is the complete portfolio of Ikarian Capital, LLC. Also check out:
1. Ikarian Capital, LLC's Undervalued Stocks
2. Ikarian Capital, LLC's Top Growth Companies, and
3. Ikarian Capital, LLC's High Yield stocks
4. Stocks that Ikarian Capital, LLC keeps buying